Navigation Links
Chronos Granules Bone Graft Substitute

ProductsChronos Granules Bone Graft Substitute
Company Synthes, Inc.
Item Chronos Granules Bone Graft Substitute
Features A synthetic cancellous bone graft substitute, which remodels into bone, is easy to use and has a clinical track record of twenty years. Its synthetic origin provides unsurpassed safety. Consists of pure beta-tricalcium phosphate and has an excellent in vivo behavior. Its strength is similar to that of cancellous bone (7.5 1 MPa), and its scaffold provides an ideal structure for osteoconductivity. Gradually resorbed and replaced by new bone, this remodelling process takes 6-18 months. Chronos can be used in all spinal applications instead of cancellous bone graft: postero-lateral fusion, interbody fusion (as cage filling material), vertebrectomies (as filling material for vertebral implants). Chronos has also indications for trauma and cranio-maxillofacial surgery.
Description Synthetic cancellous bone graft substitute (beta-tricalcium phosphate). The use of Chronos is an advantageous alternative to bone harvesting. It shortens operative time, overcomes the limitations in quantity and quality of available bone graft and avoids donor site morbidity.
Info Synthes, Inc.
Customer Service: (800) 523-0322
Web site: http://www.synthes.com

Related medicine products :

1. Conduit TCP Granules Bone Graft
2. TruGraft Synthetic Bone Graft Substitute Granules
3. Grafton Trial Frame
4. Blair-Brown Skin Graft Knife
5. Braithwaite Skin Graft Knife
6. Watson Skin Graft Knife
7. Duragen Dural Graft Matrix
8. I/C Graft Chamber, GDS010
9. I/C Graft Chamber, GDS015
10. I/C Graft Chambers, GDS005
11. Grafton DBM Crunch
Breaking Medicine Technology:For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 2For Treatment of Metastatic Colorectal Cancer, Avastin Will Face Increasing Competition From Erbitux in Europe, Most Notably in Spain 3Genoptix Announces Participation at Deutsche Bank 2009 MedTools Investor Conference 2Merieux Alliance Becomes Institut Merieux 2Merieux Alliance Becomes Institut Merieux 3Merieux Alliance Becomes Institut Merieux 4Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 57565 1Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 57565 2Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 57565 3Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 57565 4Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 57565 5Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 57565 6Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 57565 7TCT 2009 to Feature vProtect 28TM 29 Luminal Shield a Novel Treatment Designed for Soft Coronary Lesions from Prescient Medical 14134 1TCT 2009 to Feature vProtect 28TM 29 Luminal Shield a Novel Treatment Designed for Soft Coronary Lesions from Prescient Medical 14134 2Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 1Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 2Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 3Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 4Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 5Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 6Photo 3A Novartis Receives FDA Approval for Valturna 28R 29 a Single Pill Combination of valsartan and aliskiren to Treat High Blood Pressure 14132 7